IN8bio to Present at Upcoming Investor Conferences
IN8bio, Inc. (INAB)
Company Research
Source: Business Wire
NEW YORK--(BUSINESS WIRE)--IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced that William Ho, CEO and Co-founder, will present at the following investor conferences in March:TD Cowen 44th Annual Health Care ConferenceCompany presentationMonday, March 4, 2024, at 9:50 am ET2nd Annual H.C. Wainwright Cell Therapy Virtual ConferenceVirtual company presentationTuesday, March 26, 2024A live webcast and replay will be available under "Events and Presentations" in the News & Presentations section of the IN8bio website at https://investors.in8bio.com.About IN8bioIN8bio is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cell product candidates for solid and liquid tumors. Gamma-delta T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and di
Show less
Read more
Impact Snapshot
Event Time:
INAB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
INAB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
INAB alerts
High impacting IN8bio, Inc. news events
Weekly update
A roundup of the hottest topics
INAB
News
- IN8bio Doses First Patient in Phase 2 Clinical Trial of INB-400 in Newly Diagnosed Glioblastoma [Yahoo! Finance]Yahoo! Finance
- IN8bio Doses First Patient in Phase 2 Clinical Trial of INB-400 in Newly Diagnosed GlioblastomaGlobeNewswire
- IN8bio Announces Oral Presentation at the Upcoming American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting [Yahoo! Finance]Yahoo! Finance
- IN8bio Announces Oral Presentation at the Upcoming American Society of Gene & Cell Therapy (ASGCT) 2024 Annual MeetingGlobeNewswire
- IN8bio to Present at Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference [Yahoo! Finance]Yahoo! Finance
INAB
Earnings
- 11/9/23 - Beat
INAB
Sec Filings
- 4/26/24 - Form ARS
- 4/26/24 - Form DEFA14A
- 4/26/24 - Form DEF
- INAB's page on the SEC website